home / stock / qlgn / qlgn news

QLGN News and Press, Qualigen Therapeutics Inc. From 05/16/23

Stock Information
Company Name: Qualigen Therapeutics Inc.
Stock Symbol: QLGN
Market: NASDAQ
Website: qualigeninc.com
Menu
QLGN QLGN Quote QLGN Short QLGN News QLGN Articles QLGN Message Board
Get QLGN Alerts

News, Short Squeeze, Breakout and More Instantly...
QLGN - Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Design...
QLGN - Qualigen Therapeutics GAAP EPS of -$4.85 misses by $3.60, revenue of $5M beats by $3.43M

2023-05-02 17:14:48 ET Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q4 GAAP EPS of -$4.85 misses by $3.60 . Revenue of $5M (-12.3% Y/Y) beats by $3.43M . For further details see: Qualigen Therapeutics GAAP EPS of -$4.85 misses by $3.60, revenue o...

QLGN - Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing di...

QLGN - Qualigen Therapeutics' Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments...
QLGN - Qualigen Therapeutics receives non-compliance notice from Nasdaq for delayed form 10-K filing

2023-04-24 10:27:39 ET Qualigen Therapeutics ( NASDAQ: QLGN ) said it had received a letter from the Nasdaq as it had failed to file its annual report on Form 10-K for the year. In March, the Company filed notification of Late Filing on Form 12b-25, indicating that the filing ...

QLGN - Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designati...

QLGN - Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designati...
QLGN - Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

In V ivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a di...

QLGN - Petco Health and Wellness, Luminar Technologies, Akero Therapeutics among premarket losers' pack

2023-03-22 08:13:28 ET Luminar Technologies ( LAZR ) -9% . Petco Health and Wellness ( WOOF ) -9% on Q4 earnings release . Akero Therapeutics ( AKRO ) -8% . Dermata Therapeutics ( DRMA ) -7% . Qualigen Therapeutics ( QLGN ) -7%...

QLGN - Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designati...
Previous 10 Next 10